对Trastuzumab Deruxtecan的组织学不可知利用的机遇和挑战
Niraj Neupane1, Sangharsha Thapa2, Abhinav Bhattarai3,4
1Rochester General Hospital, Rochester, NY, USA.
Current oncology reports
|November 8, 2023
概括
特拉斯图苏马布德鲁克斯泰干 (T-DXd) 是一种抗体药物联合体,在先进的固体瘤中显示出泛组织学使用的前景. 对剂量,生物标志物和耐药性的进一步研究是扩大其应用的关键.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物标志物发现发现
背景情况:
- 像T-DXd这样的抗体-药物合物 (ADC) 可以改善化疗,提供生存优势.
- T-DXd在各种癌症类型中表现出广泛的活性,包括在乳腺癌,胃癌和肺癌中获得批准的指示.
- 抗癌药物的成功支持一种基于生物标志物,组织学无关的治疗方法.
研究的目的:
- 审查T-DXd的泛组织学应用潜力.
- 探索与T-DXd在先进固体瘤中的扩大使用相关的前景和挑战.
- 评估T-DXd在不同癌症组织学中的活性.
主要方法:
- 对T-DXd的当前临床试验数据的审查.
- 对最近的第二阶段试验 (DESTINY-Pantumor02, HERALD) 支持胰腺癌使用的分析.
- 评估T-DXd在生物标志物选择和HER2表达的先进固体瘤中的疗效.
主要成果:
- T-DXd表现出广泛的抗瘤活性,超出其目前批准的适用性.
- 第二期试验表明,在HER2表达或放大先进癌症中,T-DXd可能存在.
- 在各种患者群体中,T-DXd在传统化疗上显示出显著的临床优势.
结论:
- 特拉斯图苏马布德鲁克斯坦 (T-DXd) 具有广泛的活性,支持其全组织学利用潜力.
- 优化药物剂量,识别预测生物标志物和理解耐药机制对于扩大T-DXd的使用至关重要.
- 在生物标志物指导下,T-DXd的组织学不可知应用代表了癌症治疗的重大进步.
更多相关视频
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.0K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...